31 studies found for:    z4099
Show Display Options
Rank Status Study
1 Active, not recruiting Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Procedure: therapeutic conventional surgery;   Radiation: iodine I 125;   Radiation: stereotactic body radiation therapy
2 Completed The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
Condition: Parkinson's Disease
Intervention: Drug: E2007
3 Recruiting Study Of Diabetic Nephropathy With Atrasentan
Condition: Diabetic Nephropathy
Interventions: Drug: Atrasentan;   Drug: Placebo
4 Active, not recruiting Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With Peginterferon α-2a vs Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Chronic Hepatitis B(CHB).
Condition: Chronic Hepatitis B
Interventions: Drug: Tenofovir disoproxil fumarate 300 mg(TDF) and Peginterferon α-2a 180 µg(PEG);   Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a;   Drug: Tenofovir Disoproxil Fumarate;   Drug: Peginterferon α-2a
5 Available INC424 for Patients With Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis
Conditions: Myelofibrosis (PMF);   Post Polycythemia Myelofibrosis (PPV MF);   Post-essential Thrombocythemia Myelofibrosis (PET-MF);   Myelofibrosis;   Post Polycythemia Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Intervention: Drug: INC424
6 Terminated GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: GSK1605786A;   Drug: Placebo
7 Terminated Open-Label Extension Study of GSK1605786A
Condition: Crohn's Disease
Intervention: Drug: GSK1605786A
8 Completed
Has Results
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
Condition: Neoplasms, Prostate
Interventions: Drug: Dutasteride;   Drug: Placebo
9 Completed
Has Results
Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Insulin Glargine;   Drug: Insulin Lispro Premix (mid-mixture and low-mixture)
10 Completed Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
Condition: Seizure Disorder, Partial
Intervention: Drug: Pregabalin
11 Completed
Has Results
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Placebo
12 Completed
Has Results
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
Condition: Venous Thromboembolism
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Enoxaparin;   Drug: Rivaroxaban placebo;   Drug: Enoxaparin placebo
13 Recruiting Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
Condition: Heart Failure With Preserved Ejection Fraction
Interventions: Drug: LCZ696;   Drug: Valsartan
14 Completed
Has Results
Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Exenatide (AC2993);   Drug: Insulin glargine
15 Recruiting American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Conditions: Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg Strauss Syndrome;   Polyarteritis Nodosa;   Giant Cell Arteritis;   Takayasu Arteritis
Intervention:
16 Recruiting A Study of RoActemra/Actemra (Tocilizumab) in Patients With Giant Cell Arteritis
Condition: Giant Cell Arteritis
Interventions: Drug: prednisone;   Drug: prednisone placebo;   Drug: tocilizumab [RoActemra/Actemra];   Drug: tocilizumab placebo
17 Active, not recruiting Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis
Condition: Moderate to Severe Palmoplantar Psoriasis
Interventions: Biological: secukinumab 150 mg;   Biological: secukinumab 300 mg;   Biological: Placebo
18 Completed
Has Results
P4 (Pregabalin for Peripheral Posttraumatic Pain)
Condition: Neuralgia
Interventions: Drug: pregabalin;   Drug: Placebo
19 Active, not recruiting Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
Conditions: Macular Edema;   Central Retinal Vein Occlusion
Intervention: Drug: Ranibizumab 0.5 mg/0.05 ml, intravitreal injection
20 Completed REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy
Condition: Hepatitis C, Chronic
Interventions: Drug: Ribavirin;   Drug: peginterferon alfa-2a [Pegasys]

Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results
Indicates status has not been verified in more than two years